Abstract
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease with complete penetrance. Although the understanding of the cellular mechanisms that drive neurodegeneration in HD and account for the characteristic pattern of neuronal vulnerability is incomplete, defects in energy metabolism, particularly mitochondrial function, represent a common thread in studies of HD pathogenesis in animal models and humans. Here we review the metabolic dysfunction captured by in vivo proton and phosphorus magnetic resonance spectroscopy (MRS) in animal models of HD and human carriers of the mutated huntingtin protein. Having access to a presymptomatic population of individuals gives a unique possibility of approaching early pathophysiological changes in HD. Although longitudinal studies are needed to determine more precisely the time course of these metabolic changes in humans, MRS tools are already used in clinical trials to obtain proof of concepts of the ability of disease-modifying drugs to impact on disease progression in HD.
Keywords
This is a preview of subscription content, log in via an institution.
References
Squitieri F et al (1994) DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Hum Mol Genet 3(12):2103–2114
Pringsheim T et al (2012) The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord 27(9):1083–1091
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. (1993) Cell, 72(6):971–983
Langbehn DR et al (2004) A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet 65(4):267–277
Tibben A (2007) Predictive testing for Huntington’s disease. Brain Res Bull 72(2-3):165–171
MacLeod R et al (2013) Recommendations for the predictive genetic test in Huntington’s disease. Clin Genet 83(3):221–231
Tabrizi SJ et al (2009) Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8(9):791–801
Paulsen JS et al (2008) Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79(8):874–880
Duff K et al (2007) Psychiatric symptoms in Huntington’s disease before diagnosis: the predict-HD study. Biol Psychiatry 62(12):1341–1346
Paulsen JS et al (2005) Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci 17(4):496–502
Paulsen JS et al (2005) Critical periods of suicide risk in Huntington’s disease. Am J Psychiatry 162(4):725–731
Reedeker N et al (2011) Incidence, course, and predictors of apathy in Huntington’s disease: a two-year prospective study. J Neuropsychiatry Clin Neurosci 23(4):434–441
Montoya A et al (2006) Brain imaging and cognitive dysfunctions in Huntington’s disease. J Psychiatry Neurosci 31(1):21–29
Vonsattel JPG, Keller C, Amaya MDP (2008) Neuropathology of Huntington’s disease. In: Litvan CDAI (ed) Handbook of clinical neurology. Elsevier B. V, Amsterdam
Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57(5):369–384
Mitchell IJ, Cooper AJ, Griffiths MR (1999) The selective vulnerability of striatopallidal neurons. Prog Neurobiol 59(6):691–719
Zuccato C, Cattaneo E (2014) Huntington’s disease. Handb Exp Pharmacol 220:357–409
Ross CA et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10(4):204–216
Gines S et al (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington’s disease knock-in mice. Hum Mol Genet 12(5):497–508
Milakovic T, Johnson GV (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280(35):30773–30782
Antonini A et al (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease. Brain 119(Pt 6):2085–2095
Grafton ST et al (1992) Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington’s disease. Arch Neurol 49(11):1161–1167
Kuwert T et al (1993) Striatal glucose consumption in chorea-free subjects at risk of Huntington’s disease. J Neurol 241(1):31–36
Browne SE, Beal MF (2004) The energetics of Huntington’s disease. Neurochem Res 29(3):531–546
Tabrizi SJ et al (1999) Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol 45(1):25–32
Cui L et al (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127(1):59–69
Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1(6):361–370
Lin J et al (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119(1):121–135
Palfi S et al (1996) Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington’s disease. J Neurosci 16(9):3019–3025
Brouillet E et al (1998) Partial inhibition of brain succinate dehydrogenase is sufficient to initiate striatal degeneration in rat. J Neurochem 70(2):794–805
Tabrizi SJ et al (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12(7):637–649
Mochel F et al (2010) Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington’s disease. Eur J Hum Genet 18(9):1057–1060
Kar K et al (2013) beta-hairpin-mediated nucleation of polyglutamine amyloid formation. J Mol Biol 425(7):1183–1197
Pedersen JT, Heegaard NH (2013) Analysis of protein aggregation in neurodegenerative disease. Anal Chem 85(9):4215–4227
Beal MF et al (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13(10):4181–4192
Jenkins BG et al (1996) Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 16(3):450–461
Dautry C et al (1999) Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol Dis 6(4):259–268
Matthews RT et al (1998) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington’s disease. J Neurosci 18(1):156–163
Henry PG et al (2002) Decreased TCA cycle rate in the rat brain after acute 3-NP treatment measured by in vivo 1H-[13C] NMR spectroscopy. J Neurochem 82(4):857–866
Mochel F et al (2012) Early alterations of brain cellular energy homeostasis in Huntington disease models. J Biol Chem 287(2):1361–1370
Tkac I et al (2001) Metabolic changes in quinolinic acid-lesioned rat striatum detected non- invasively by in vivo 1H NMR spectroscopy. J Neurosci Res 66(5):891–898
Jenkins BG et al (2000) Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington’s disease mice. J Neurochem 74(5):2108–2119
Mangiarini L et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493–506
Jenkins BG et al (2005) Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington’s disease. J Neurochem 95(2):553–562
van Dellen A et al (2000) N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington’s disease mice. Neuroreport 11(17):3751–3757
Jenkins BG et al (1998) 1H NMR spectroscopy studies of Huntington’s disease: correlations with CAG repeat numbers. Neurology 50(5):1357–1365
Tkac I et al (2007) Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy. J Neurochem 100(5):1397–1406
Zacharoff L et al (2012) Cortical metabolites as biomarkers in the R6/2 model of Huntington’s disease. J Cereb Blood Flow Metab 32(3):502–514
Zacharoff L et al. (2010) Biochemical changes in Q140 striatum precedes progressive volume loss. In: Proceedings of the society for neuroscience. San Diego, CA
Zacharoff L et al. (2011) Striatum specific lactate change in BACHD model of Huntington’s disease. In: Proceedings of the society for neuroscience. Washington, DC.
Heikkinen T et al (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington’s disease. PLoS One 7(12), e50717
Wheeler VC et al (1999) Length-dependent gametic CAG repeat instability in the Huntington’s disease knock-in mouse. Hum Mol Genet 8(1):115–122
Wheeler VC et al (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9(4):503–513
Tkac I et al (2012) Homeostatic adaptations in brain energy metabolism in mouse models of Huntington disease. J Cereb Blood Flow Metab 32(11):1977–1988
Mochel F et al (2012) Abnormal response to cortical activation in early stages of Huntington disease. Mov Disord 27(7):907–910
Kim J et al (2010) Reduced creatine kinase as a central and peripheral biomarker in Huntington’s disease. Biochim Biophys Acta 1802(7-8):673–681
Wheeler VC et al (2002) Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 11(6):633–640
Chaumeil MM et al (2012) pH as a biomarker of neurodegeneration in Huntington’s disease: a translational rodent-human MRS study. J Cereb Blood Flow Metab 32(5):771–779
Cui W et al (2013) Non-invasive measurement of cerebral oxygen metabolism in the mouse brain by ultra-high field 17O MR spectroscopy. J Cereb Blood Flow Metab 33(12):1846–1849
Nikas JB, Keene CD, Low WC (2010) Comparison of analytical mathematical approaches for identifying key nuclear magnetic resonance spectroscopy biomarkers in the diagnosis and assessment of clinical change of diseases. J Comp Neurol 518(20):4091–4112
Nikas JB, Low WC (2011) Application of clustering analyses to the diagnosis of Huntington disease in mice and other diseases with well-defined group boundaries. Comput Methods Programs Biomed 104(3):e133–e147
Hess AT et al (2011) Real-time motion and B0 corrected single voxel spectroscopy using volumetric navigators. Magn Reson Med 66(2):314–323
Keating B, Ernst T (2012) Real-time dynamic frequency and shim correction for single-voxel magnetic resonance spectroscopy. Magn Reson Med 68(5):1339–1345
Deelchand DK, Iltis I, Henry PG (2014) Improved quantification precision of human brain short echo-time 1H magnetic resonance spectroscopy at high magnetic field: a simulation study. Magn Reson Med 72(1):20–25
Harms L et al (1997) Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington’s disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry 62(1):27–30
Jenkins BG et al (1993) Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized 1H NMR spectroscopy. Neurology 43(12):2689–2695
Sanchez-Pernaute R et al (1999) Clinical correlation of striatal 1H MRS changes in Huntington’s disease. Neurology 53(4):806–812
Taylor-Robinson SD et al (1996) Proton magnetic resonance spectroscopy in Huntington’s disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 11(2):167–173
Hoang TQ et al (1998) Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington’s and Parkinson’s diseases. Neurology 50(4):1033–1040
Sturrock A et al (2010) Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 75(19):1702–1710
Padowski JM et al (2014) Neurochemical correlates of caudate atrophy in Huntington’s disease. Mov Disord 29(3):327–335
van den Bogaard SJ et al (2011) Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington’s disease provides in vivo evidence for impaired energy metabolism. J Neurol 258(12):2230–2239
Unschuld PG et al (2012) Brain metabolite alterations and cognitive dysfunction in early Huntington’s disease. Mov Disord 27(7):895–902
Ruocco HH et al (2007) Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopy. Mov Disord 22(14):2052–2056
van Oostrom JC et al (2007) 1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain Res 1168:67–71
Gomez-Anson B et al (2007) Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology 68(12):906–910
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mochel, F., Dubinsky, J.M., Henry, PG. (2016). Magnetic Resonance Spectroscopy in Huntington’s Disease. In: Öz, G. (eds) Magnetic Resonance Spectroscopy of Degenerative Brain Diseases. Contemporary Clinical Neuroscience. Springer, Cham. https://doi.org/10.1007/978-3-319-33555-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-33555-1_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33553-7
Online ISBN: 978-3-319-33555-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)